Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

European Medicines Agency

Lack of evidence that cancer drugs approved by the EMA improve survival

BMJ published a study investigating the effectiveness of 48 drugs approved by the European Medicines Agency.

Many new drugs for cancer are approved on the basis of surrogate endpoints, which may not accurately predict the treatment’s impact on survival and quality of life.

In a study in the BMJ (4 October 2017), researchers reviewed published data on 48 drugs approved for 68 indications by the European Medicines Agency (EMA) from 2009 to 2013[1]

They found that at the time of approval, 24 (35%) indications had evidence of prolonged survival and 7 (10%) improved quality of life compared with existing treatment options or placebo. In the post-marketing period, there was evidence of prolonged survival for an additional 3 (7%) indications and improved quality of life for 5 (11%) indications. Over a median of 5.4 years’ follow-up, only 35 (51%) had shown a significant improvement in survival or quality of life, while 33 (49%) remained uncertain.

The researchers said the findings indicated that it is extremely rare for evidence to confirm that new cancer drugs impact positively upon survival and quality of life following their approval.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203968

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Community Pharmacy Handbook

    Community Pharmacy Handbook

    Community Pharmacy Handbook is a survival guide for community pharmacists and students, answering your practical questions. Includes case studies.

    £32.00Buy now
  • Workplace Drug Testing

    Workplace Drug Testing

    Explains drug testing regulatory frameworks and all aspects of drug analysis. Case studies of successful programmes are included.

    £79.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £42.00Buy now
  • Remington Education: Pharmaceutics

    Remington Education: Pharmaceutics

    Case studies and MCQs explaining the pharmaceutics behind drug delivery.

    £32.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £24.00Buy now
  • Nutraceuticals


    This authoritative text assesses the medical and scientific evidence for the use of nutraceuticals. Includes monographs on 25 nutraceuticals such as soy and tea.

    £37.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Cancer drugs in preparation for chemotherapy

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.